АНУ-ын Хүнс, эмийн чанарын хяналтын газар (FDA) Тайленол (Tylenol) болон напроксен натрийн хослол бүхий шинэ эмийг бүртгэж, зах зээлд гаргахыг зөвшөөрлөө. Kenvue компанийн үйлдвэрлэж буй энэхүү шинэ бүтээгдэхүүн нь толгой, нуруу, булчин болон шүдний өвдөлт, мөн сарын тэмдгийн өвдөлт, үе мөчний хөнгөн өвдөлтийг намдаахад зориулагдсан бөгөөд хэрэглэснээс хойш 30 минутын дотор үйлчилж, 12 цаг хүртэл үргэлжилдэг байна.

Published:

Энэхүү мэдээ, нийтлэлийг хиймэл оюун боловсруулав.

FDA уг эмийг худалдаанд гаргах онцгой эрхийг Kenvue компанид гурван жилийн хугацаатай олгосон бөгөөд удахгүй АНУ-ын даяар эмийн сангуудаар худалдаалагдаж эхлэх юм. Тус компаниас мэдээлснээр, энэхүү хослол нь опиоид агуулаагүй тул донтох эрсдэлгүй, жоргүйгээр авах боломжтой өвчин намдаах үр дүнтэй шийдэл болно гэж үзэж байна.

Энэхүү шийдвэр нь АНУ-ын ерөнхийлөгч Дональд Трамп болон Эрүүл мэнд, хүний үйлчилгээний сайд Роберт Ф.Кеннеди нарын байр суурьтай зөрчилдөж байна. Тэд Тайленолыг жирэмсэн үед хэрэглэх нь хүүхдэд аутизмын эрсдэлийг нэмэгдүүлдэг гэж мэдэгдсээр ирсэн боловч АНУ-ын Эх барих, эмэгтэйчүүдийн эмч нарын коллеж энэхүү нотолгоог үгүйсгэж, шинжлэх ухааны үндэслэлгүй болохыг мэдэгдсэн юм.

Дэлгэрэнгүйг эх сурвалжаас харах

↓Эх сурвалжийг нээх ↓

<![CDATA[{"className":"sc-1ge0fwe-0","newsletterData":{"pianoFieldName":"receiveEveningHeadlinesUSNews","regTitle":"Evening Headlines","subscriptionGroup":"us_evening_headlines","subscriptionGroupId":"4326e634-422a-4447-8e1e-604a937cd3b5","type":"daily_news","pathPrefix":["/us","/news/world/americas","/news/world/americas/crime"],"title":"The latest headlines from our reporters across the US sent straight to your inbox each weekday","mobileTitle":"Your briefing on the latest headlines from across the US","imageSrc":"https://static.independent.co.uk/static-assets/images/newsletters/usEveningHeadlines1_1.png","label":"I would like to receive morning headlines Monday – Friday plus breaking news alerts by email“,”newsletterKey”:”receiveEveningHeadlines”,”regSourceSection”:”Americas”,”regSourceNewsletter”:”NSC”},”isClimate”:false}]]>

A new version of over-the-counter Tylenol – this one combined with naproxen sodium – has gotten approval from the Food and Drug Administration.

The tablet is designed for temporary relief of minor aches and pains, such as headache, backache, muscular aches, toothache, menstrual cramps and minor arthritis pain. Kenvue, which manufactures Tylenol and Tylenol with Naproxen, said the new drug starts working within 30 minutes and offers pain relief for up to 12 hours.

Kenvue said that the new medication will soon be available at shops across the United States.

The federal approval comes despite the Trump administration pushing the idea that Tylenol is dangerous for expecting mothers. Without scientific backing, President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. have said that taking Tylenol while pregnant increases the risk of autism.

The Food and Drug Administration approved a new version of Tylenol, one that is combined with naproxen sodium
The Food and Drug Administration approved a new version of Tylenol, one that is combined with naproxen sodium (AFP/Getty)

The FDA granted Kenvue a three-year period of exclusivity for its new over-the-counter formulation.

“This milestone reflects the long-standing leadership of Tylenol in translating rigorous clinical science into accessible, over‑the‑counter solutions,” said Rajesh Mishra MD, the chief medical officer at Kenvue, in a statement. “Persistent pain often leaves people trapped in a cycle of trial and error, navigating between choosing short-term relief or more complex treatment options.”

cookie.trim() === ‘__DEBUG__=true’)) { console.log(‘Ad logs: “mpu1”, renderedAtParagraph: 3’); }]]>

cookie.trim() === ‘__DEBUG__=true’)) { console.log(‘Ad logs: “mpu1”, injectedAtParagraph: 4’); }]]>

The drug combo does not contain opioids. Kenvue noted that the US Department of Labor reports that up to 1 in 4 people prescribed opioids are at risk of addiction.

“Tylenol with Naproxen addresses this gap by combining two well-established non-opioid pain relievers into a single, clinically proven [over-the-counter] therapeutic solution that requires no prescription and carries no opioid risk,” Kenvue officials said in their statement.

President Donald Trump and Health and Human Services Secretary Robert F Kennedy Jr have pushed the idea that Tylenol is dangerous for expecting mothers
President Donald Trump and Health and Human Services Secretary Robert F Kennedy Jr have pushed the idea that Tylenol is dangerous for expecting mothers (Reuters)

Trump has previously made disputed and unproven claims that Tylenol, known as paracetamol elsewhere, is linked to autism and advised pregnant women to stop taking it last September. The American College of Obstetricians and Gynecologists disputed the link made by Trump.

cookie.trim() === ‘__DEBUG__=true’)) { console.log(‘Ad logs: “taboola-carousel-thumbnails”, injectedAtParagraph: 7’); }]]>

Dr. Steven Fleischman, the president of the group, said the Tylenol claim “is not backed by the full body of scientific evidence and dangerously simplifies the many and complex causes of neurologic challenges in children.”

cookie.trim() === ‘__DEBUG__=true’)) { console.log(‘Ad logs: “mpu2”, renderedAtParagraph: 8’); }]]>

cookie.trim() === ‘__DEBUG__=true’)) { console.log(‘Ad logs: “mpu2”, injectedAtParagraph: 8’); }]]>

“Studies that have been conducted in the past, show no clear evidence that proves a direct relationship between the prudent use of acetaminophen during any trimester and fetal developmental issues,” the statement added.

- Зар сурталчилгаа -

Та юу гэж бодож байна?

Сэтгэгдлээ оруулна уу!
Please enter your name here

MFC.mn сайтад сэтгэгдэл оруулахад анхаарах зүйлс

Холбоотой

spot_img

Шинэ

spot_img